below link is to a very respected virologist's blog (Dr. Vincent Racaniello: i get it sent to my email inbox -- you can too). the good news in this week's blog is that there is an XMRV conference happening this month!! (this is being discussed on another thread already.) and the virologist blogger says that the retroviral community has clearly embraced XMRV. yaaaaaay! i love the retroviral community!!!!! they are my new best friend. the bad news is that two HIV/AIDS drug manufacturers have been found guilty of making antiviral drugs that are contaminated with a pig virus. these are the same companies that would make XMRV meds. ugh.
- rrrr
<http://www.virology.ws>
virology blog
<#1>Porcine circovirus DNA found in RotaTeq
<#2>XMRV at Cold Spring Harbor
<#3>Virology lecture #21: Antivirals
Posted: 07 May 2010 09:43 AM PDT
The US Food and Drug Administration recently*<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm205625.htm>recommended that administration of Glaxo SmithKline’s Rotarix vaccine, which protects against rotavirus infection, be suspended after an independent research group found that the <http://www.virology.ws/2010/03/22/porcine-circovirus-dna-in-rotavirus-vaccine/>vaccine contains DNA of porcine circovirus type 1. Now the FDA reports finding circovirus DNA in the rotavirus vaccine made by Merck:
FDA recently received information from Merck & Co, Inc. that its preliminary studies have identified fragments of DNA from PCV1 and from a related porcine circovirus type 2 (PCV2) in its RotaTeq vaccine. Merck’s findings suggest that the number of PCV DNA fragments in its vaccine may be smaller than what has been found in Rotarix.
FDA has so far not recommended suspension of RotaTeq use. The Vaccines and Related Biological Products Advisory Committee meets today, after which*FDA will make further recommendations on the use of the licensed rotavirus vaccines in the United States.
The source of porcine circovirus type 1 DNA in both Rotarix and RotaTeq is likely to be trypsin used during propagation of the cell cultures necessary for vaccine production. The enzyme is produced from porcine pancreas.
<http://feedproxy.google.com/~r/VirologyBlog/~3/8JNHifK_FIM/?utm_source=feedburner&utm_medium=email>XMRV at Cold Spring Harbor
Posted: 07 May 2010 08:04 AM PDT
<http://cshl.org> Cold Spring Harbor Laboratory (CSHL) is a private, non-profit institution located in the eponymous town on Long Island, New York. Over 400 scientists work there on a wide range of biological problems, including cancer, neurobiology, plant genetics, and genomics. CSHL has a storied research history, having hosted nine Nobel Laureates. But it is also well known for its world class scientific conferences. The first of these was the Cold Spring Harbor Laboratory Symposium on Quantitative Biology, which was held in 1934. Another well known event is the Phage Course, founded by Salvador Luria and Max Delbrck in 1948.*There are now over <http://meetings.cshl.edu/meetings.html>24 meetings held annually. One of these is the meeting on retroviruses, which will begin on 24 May 2010. Below is a list of the presentations about XMRV, the new retrovirus implicated in prostate cancer and chronic fatigue syndrome. The author presenting each study can be found at the <http://meetings.cshl.edu/meetings/abstracts/2010retro_absstat.html>meeting website.
Failure to detect XMRV in human prostate tumors
Development of a multiplex serological assay to detect XMRV antibodies
Characterization of cellular determinants required for infection of XMRV, a novel retrovirus associated with human familial prostate cancer
Screening mouse genomes For XMRV-Like Elements
Development of highly sensitive assays for the detection of XMRV nucleic acids in clinical samples
Compounds that inhibit replication of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome
Investigation of XMRV as a human pathogen
Investigations into XMLV-related virus infection
XMRV is not detected in Quebec patients with chronic fatigue syndrome
Wild-derived mouse strain (Mus pahari) as a small animal model for XMRV infection
XMRV tropism in hematopoietic cells
Evidence for sequence variation in XMRV
The human retrovirus XMRV produces rare transformation events in cell culture but does not have direct transforming activity
The XMRV is inhibited by APOBEC3 proteins and anti-HIV-1 drugs
Immune responses in XMRV-infected rhesus macaques—Serological markers of XMRV infection
XMRV Is inhibited by interferon independently of RNase L or Tetherin
Comparison of XMRV infections in humans and rhesus macaques
Susceptibility of XMRV to antiretroviral inhibitors
Integration site analysis in XMRV-positive prostate cancers
Xpr1 is necessary but not sufficient for XMRV entry
Effects of interferon regulated proteins, RNase L and APOBEC3G, on XMRV replication
The retrovirus community has clearly embraced XMRV, a virus discovered just <http://www.ncbi.nlm.nih.gov/pubmed/16609730>four years ago. This high level of activity means that there will be many papers on XMRV in the scientific literature in the next year. I’m looking forward to discussing them with the readers of virology blog.
- rrrr
<http://www.virology.ws>
virology blog
<#1>Porcine circovirus DNA found in RotaTeq
<#2>XMRV at Cold Spring Harbor
<#3>Virology lecture #21: Antivirals
Posted: 07 May 2010 09:43 AM PDT
The US Food and Drug Administration recently*<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm205625.htm>recommended that administration of Glaxo SmithKline’s Rotarix vaccine, which protects against rotavirus infection, be suspended after an independent research group found that the <http://www.virology.ws/2010/03/22/porcine-circovirus-dna-in-rotavirus-vaccine/>vaccine contains DNA of porcine circovirus type 1. Now the FDA reports finding circovirus DNA in the rotavirus vaccine made by Merck:
FDA recently received information from Merck & Co, Inc. that its preliminary studies have identified fragments of DNA from PCV1 and from a related porcine circovirus type 2 (PCV2) in its RotaTeq vaccine. Merck’s findings suggest that the number of PCV DNA fragments in its vaccine may be smaller than what has been found in Rotarix.
FDA has so far not recommended suspension of RotaTeq use. The Vaccines and Related Biological Products Advisory Committee meets today, after which*FDA will make further recommendations on the use of the licensed rotavirus vaccines in the United States.
The source of porcine circovirus type 1 DNA in both Rotarix and RotaTeq is likely to be trypsin used during propagation of the cell cultures necessary for vaccine production. The enzyme is produced from porcine pancreas.
<http://feedproxy.google.com/~r/VirologyBlog/~3/8JNHifK_FIM/?utm_source=feedburner&utm_medium=email>XMRV at Cold Spring Harbor
Posted: 07 May 2010 08:04 AM PDT
<http://cshl.org> Cold Spring Harbor Laboratory (CSHL) is a private, non-profit institution located in the eponymous town on Long Island, New York. Over 400 scientists work there on a wide range of biological problems, including cancer, neurobiology, plant genetics, and genomics. CSHL has a storied research history, having hosted nine Nobel Laureates. But it is also well known for its world class scientific conferences. The first of these was the Cold Spring Harbor Laboratory Symposium on Quantitative Biology, which was held in 1934. Another well known event is the Phage Course, founded by Salvador Luria and Max Delbrck in 1948.*There are now over <http://meetings.cshl.edu/meetings.html>24 meetings held annually. One of these is the meeting on retroviruses, which will begin on 24 May 2010. Below is a list of the presentations about XMRV, the new retrovirus implicated in prostate cancer and chronic fatigue syndrome. The author presenting each study can be found at the <http://meetings.cshl.edu/meetings/abstracts/2010retro_absstat.html>meeting website.
Failure to detect XMRV in human prostate tumors
Development of a multiplex serological assay to detect XMRV antibodies
Characterization of cellular determinants required for infection of XMRV, a novel retrovirus associated with human familial prostate cancer
Screening mouse genomes For XMRV-Like Elements
Development of highly sensitive assays for the detection of XMRV nucleic acids in clinical samples
Compounds that inhibit replication of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome
Investigation of XMRV as a human pathogen
Investigations into XMLV-related virus infection
XMRV is not detected in Quebec patients with chronic fatigue syndrome
Wild-derived mouse strain (Mus pahari) as a small animal model for XMRV infection
XMRV tropism in hematopoietic cells
Evidence for sequence variation in XMRV
The human retrovirus XMRV produces rare transformation events in cell culture but does not have direct transforming activity
The XMRV is inhibited by APOBEC3 proteins and anti-HIV-1 drugs
Immune responses in XMRV-infected rhesus macaques—Serological markers of XMRV infection
XMRV Is inhibited by interferon independently of RNase L or Tetherin
Comparison of XMRV infections in humans and rhesus macaques
Susceptibility of XMRV to antiretroviral inhibitors
Integration site analysis in XMRV-positive prostate cancers
Xpr1 is necessary but not sufficient for XMRV entry
Effects of interferon regulated proteins, RNase L and APOBEC3G, on XMRV replication
The retrovirus community has clearly embraced XMRV, a virus discovered just <http://www.ncbi.nlm.nih.gov/pubmed/16609730>four years ago. This high level of activity means that there will be many papers on XMRV in the scientific literature in the next year. I’m looking forward to discussing them with the readers of virology blog.
